Finland· FI-REL-REL56006
Tecartus
A brexucabtagene autoleucel product containing brexucabtagene autoleucel, registered in Finland by Kite Pharma EU B.V.. The same ATC class is registered in 13 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Brexucabtagene autoleucel is registered in 13 of 19 countries.
Countries holding a registration under ATC L01XL06 (brexucabtagene autoleucel), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 8 of them publish a price we can compare per daily dose
Brexucabtagene autoleucel · ATC L01XL06
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Brexucabtagene autoleucel
- Manufacturer
- Kite Pharma EU B.V.
- Country
- Finland (FI)
- ATC code
- L01XL06
- ATC class
- Brexucabtagene autoleucel
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
82 interactions on record for brexucabtagene autoleucel.
Graded by severity as the source publishes them — 51 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Brexucabtagene autoleucel · interactions on record
82 records
- 51 severe
- 31 moderate
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Brexucabtagene autoleucel in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesTECARTUSKite Pharma, Inc.
- CanadaTECARTUSGILEAD SCIENCES CANADA INC
- SpainTECARTUS 0,4 - 2 x 10e8 CELULAS DISPERSION PARA PERFUSIONKite Pharma Eu B.V.
- United KingdomTecartus 40million-200million cells/68ml dispersion for infusion bagsGilead Sciences Ltd
- BelgiumTecartus 0.4 10*8 cells/ml - 2 10*8 cells/mlKite Pharma EU
- NetherlandsTecartus 0.4-2.0 x 10^8 cellen, dispersie voor infusieKite Pharma EU B.V.
- NorwayTecartusKite Pharma EU B.V.
- PolandTecartusKite Pharma EU B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tecartus
- Liechtenstein · Tecartus
- Norway · Tecartus
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ebc2dd3e-39f8-43be-9aa6-d6c8aa524cf1 GET /v1/drugs/ebc2dd3e-39f8-43be-9aa6-d6c8aa524cf1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "infuusioneste, dispersio",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "0.4 - 2 x 10exp8 solua",
"atc_label": "breksukabtageeniautoleuseeli",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/20/1492/001",
"fimea_rel_id": "REL56006",
"authorised_at": "2020-12-14"
}See everything about brexucabtagene autoleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.